VistaGen Therapeutics Receives European Patent for AV-101 for Treatment of Depression - Markets Insider

VistaGen Therapeutics Receives European Patent for AV-101 for Treatment of DepressionMarkets InsiderVistaGen is preparing to advance AV-101 into a 180-patient, U.S. multi-center, Phase 2 adjunctive treatment study in adult MDD patients with an inadequate response to standard, FDA-approved antidepressants, with Dr. Maurizio Fava of Harvard University ...and more »